MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth

Medtronic (MDT) is anticipated to report fiscal Q2 2026 revenues of $8.86 billion, a 5.4% year-over-year increase, and EPS of $1.31, up 4%, following a consistent track record of exceeding estimates in prior quarters. Growth is expected to be primarily driven by the Cardiovascular segment, projected to rise 8.4% due to strong device uptake in PFA and TAVR, and the Diabetes unit, forecast for 9.2% growth from MiniMed 780G and Simplera Sync, with the latter also undergoing a strategic spin-off into "MiniMed" to concentrate on high-margin markets. The Neuroscience and Medical Surgical segments are also expected to contribute positively with projected revenue increases of 1.5% and 5.4%, respectively.

Analysis

Medtronic (MDT) is slated to report fiscal Q2 2026 results on November 18th, with consensus estimates projecting revenues of $8.86 billion, a 5.4% year-over-year improvement, and EPS of $1.31, marking a 4% increase. This follows a consistent pattern of exceeding Zacks Consensus Estimates in the preceding four quarters, with an average earnings surprise of 2.20%. Earnings estimates have remained stable over the past 60 days.

Key growth drivers are anticipated from the Cardiovascular and Diabetes segments. Cardiovascular revenues are expected to rise 8.4% year-over-year, propelled by strong uptake of PulseSelect and Affera Sphere-9 PFA systems, traction from the Evolut FX+ TAVR device, and benefits from a competitor's market exit. The Diabetes unit is forecast for a 9.2% revenue increase, driven by the MiniMed 780G and Simplera Sync sensors, alongside recent FDA approvals for the SmartGuard algorithm and MiniMed 780G for Type 2 Diabetes.

The Neuroscience and Medical Surgical segments are also projected to contribute positively, with expected revenue growth of 1.5% and 5.4% respectively, supported by product innovations like the AiBLE spine technology and the AI-powered Touch Surgery ecosystem. Medtronic is also advancing the strategic separation of its Diabetes unit into a standalone company, MiniMed, a move designed to sharpen the company's focus on high-margin growth areas such as PFA and renal denervation.

Despite these positive operational indicators and historical outperformance, Medtronic currently holds a Zacks Earnings ESP of 0.00% and a Zacks Rank #3 (Hold). This combination, according to the Zacks model, suggests a lower probability of an earnings beat for the upcoming quarter, which warrants attention given the company's prior success in surpassing estimates.

Key Decisions for Investors

• Monitor Medtronic's Q2 2026 earnings report closely for actual segment-specific growth rates, especially in Cardiovascular and Diabetes, to validate the projected strong performance.
• Evaluate the progress and strategic implications of the Diabetes unit spin-off into MiniMed, as this restructuring could unlock value and refine Medtronic's long-term growth profile in higher-margin markets.
• Consider the Zacks Earnings ESP of 0.00% and Zacks Rank #3 as a potential indicator of limited upside surprise for the upcoming quarter, despite Medtronic's historical earnings beats.